Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
Status:
Completed
Trial end date:
2018-10-27
Target enrollment:
Participant gender:
Summary
Non Small Cell Lung Cancer (NSCLC) represents the first cancer related cause of death
worldwide with 1.4 millions of deaths every years. Current standard therapies include
platinum-containing drugs but at one year from diagnosis the survival rate is still low
(30-40%) .
The purpose of this study is to evaluate the role of a platinum-free drug, named Vinorelbine,
administered by the so called "metronomic schedule" in order to prolong the progression free
survival of patients.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano